Genetics of pheochromocytoma and paraganglioma: New developments;Génétique des phéochromocytomes et paragangliomes: Nouveaux développements

Annales d'Endocrinologie

Volumn 71, Issue 2, 2010, Pages 76-82

  Pigny, P ^a   Cardot Bauters, C ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Molecular genetics; Paraganglioma; Pheochromocytoma; Susceptibility genes

Indexed keywords

KINESIN; NEUROFIBROMIN; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROTEIN KIF1B BETA; PROTEIN RET; SUCCINATE DEHYDROGENASE; SUCCINATE DEHYDROGENASE A; SUCCINATE DEHYDROGENASE B; SUCCINATE DEHYDROGENASE C; SUCCINATE DEHYDROGENASE D; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

APOPTOSIS; CANCER GENETICS; CARCINOGENESIS; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; HEAD AND NECK TUMOR; HUMAN; HYPOXIA; INHERITANCE; LINKAGE ANALYSIS; MOLECULAR INTERACTION; NERVE CELL DIFFERENTIATION; NEURAL CREST CELL; PARAGANGLIOMA; PATHOGENESIS; PATIENT IDENTIFICATION; PATIENT SELECTION; PHEOCHROMOCYTOMA; REVIEW; TUMOR VASCULARIZATION;

EID: 77952953844     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ando.2009.11.004     Document Type: Review

References (31)

1. Neumann H.P., Berger D.P., Sigmund G., Blum U., Schmidt D., Parmer R.J., et al. Pheochromocytomas, MEN type 2 and von Hippel Lindau disease. N Engl J Med 1993, 329:1531-1538.
2. Bravo E.L., Gifford R.W. Pheochromocytoma: diagnostic, localization and management. N Engl J Med 1984, 311:298-303.
3. Jalil N.D., Pattou F.N., Combemale F., Chapuis Y., Henry J.F., Peix J.L., et al. Effectiveness and limits of preoperative imaging studies for the localization of pheochromocytomas and paragangliomas: a review of 282 cases. Eur J Surg 1998, 164:23-28.
4. Baysal B.E. Hereditary paraganglioma targets diverse paraganglia. J Med Genet 2002, 39:617-622.
5. van der Mey A.G., Maaswinkel-Mooy P.D., Cornelisse C.J., Schmidt P.H., van de Kamp J.J. Genomic imprinting in hereditary glomus tumours: evidence for new genetic theory. Lancet 1989, 2:1291-1294.
6. Baysal B.E., Ferrell R.E., Willett-Brozick J.E., Lawrence E.C., Myssiorek D., Bosch A., et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 2000, 287:848-851.
7. Niemann S., Muller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet 2000, 26:268-270.
8. Astuti D., Latif F., Dallol A., Dahia P.L., Douglas F., George E., et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet 2001, 69:49-54.
9. Baysal B.E. Genomic imprinting and environment in hereditary paraganglioma. Am J Med Genet 2004, 129C:85-90.
10. Neumann H.P., Bausch B., McWhinney S.R., Bender B.U., Gimm O., Franke G., et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 2002, 346:1459-1466.
11. Bauters C., Vantyghem M.C., Leteurtre E., Odou M.F., Mouton C., Porchet N., et al. Hereditary phaeochromocytomas and paragangliomas: a study of 5 susceptibility genes. J Med Genet 2003, 40:e75.
12. Reik W., Walter J. Genomic imprinting: parental influence on the genome. Nat Rev Genet 2001, 2:21-32.
13. Hensen E.F., Jordanova E.S., van Minderhout I.J.H.M., Hogendoorn P.C.W., Taschner P.E.M., et al. Somatic loss of maternal chromosome 11 causes parent-of-origin-dependant inheritance in SDHD-linked paraganglioma and phaechromocytoma families. Oncogene 2004, 23:4076-4083.
14. Pigny P., Vincent A., Cardot-Bauters C., Bertrand M., Thomas de Montpreville V., et al. Paraganglioma after maternal transmission of a succinate dehydrogenase gene mutation. J Clin Endocrinol Metab 2008, 93:1609-1615.
15. Hensen E.F., Jansen J.C., Siemers M.D., Oosterwijk J.C., Vriends A.H.J.T., Corssmit E.P.M., et al. The Dutch founder mutation SDHD D92Y shows a reduced penetrance for the development of paragangliomas in large multigenerational family. Eur J Hum Genet 2009, 8. [ahead of print].
16. Burnichon N., Rohmer V., Amar L., Herman P., Leboulleux S., Darrouzet V., et al. The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas. J Clin Endocrinol Metab 2009, 94:2817-2827.
17. Gimenez-Roqueplo A.P., Favier J., Rustin P., Mourad J.J., Plouin P.F., Corvol P., et al. The R22X mutation of the SDHD gene in hereditary paraganglioma abolishes the enzymatic activity of complex II in the mitochondrial respiratory chain and activates the hypoxia pathway. Am J Hum Genet 2001, 69:1186-1197.
18. Atkins D.J., Gingert C., Justenhoven C., Schmahl G.E., Bonato M.S., Brauch H., et al. Concomitant deregulation of HIFalpha and cell cycle proteins in VHL mutated renal cell carcinomas. Virchows Arch. 2005, 447:634-642.
19. Dahia P.L.M., Ross K.N., Wright M.E., Hayashida C.Y., Santagata S., Barontini M., et al. A HIF1α regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet 2005, 1:e8.
20. Roe J.S., Kim H., Lee S.M., Kim S.T., Cho E.J., Youn H.D. P53 stabilization and transactivation by a von Hippel Lindau protein. Mol Cell 2006, 22:395-405.
21. Forman J.R., Worth C.L., Bickerton G.R.J., Eisen T.G., Blundell T.L. Structural bioinformatics mutation analysis reveals genotype-phenotype correlations in von Hippel Lindau disease and suggests molecular mechanisms of tumourigenesis. Proteins 2009, 77:84-96.
22. Lee S., Nakamura E., Yang H., Wei W., Linggi M.S., Sajan M.P., et al. Neuronal apoptosis linked to EglN3 prolylhydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell. 2005, 8:155-167.
23. Maxwell P.H. A common pathway for genetic events leading to pheochromocytoma. Cancer Cell 2005, 8:91-93.
24. Schlisio S., Kenchappa R.S., Vredeveld L.C.W., George R.E., Stewart R., Greulich H., et al. The kinesin KIF1Bβ acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev. 2008, 22:884-893.
25. Yeh I.T., Lenci R.E., Qin Y., Buddavarapu K., Ligon A.H., Leteurtre E., et al. A germline mutation of the KIF1Bβ gene on 1p36 family with neural and nonneural tumors. Hum Genet 2008, 124:279-285.
26. Ladroue C., Carcenac R., Leporrier M., Gad S., Le Hello C., Galateau-Salle F., et al. PHD2 mutation and congenital erythrocytosis with paraganglioma. N Engl J Med. 2008, 359:2685-2692.
27. Pollard P.J., Ratcliffe P.J. Puzzling patterns of predisposition. Science 2009, 324:192-194.
28. Hao H.-X., Khalimonchuk O., Schraders M., Dephoure N., Bayley J.P., Kunst H., et al. SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science 2009, 325:1139-1142.
29. Pigny P., Cardot-Bauters C., Do Cao C., Vantyghem M.C., Carnaille B., Pattou F., et al. Should genetic testing be formed in each patient with sporadic pheochromocytoma at presentation?. Eur J Endocrinol. 2009, 160:227-231.
30. Erlic Z., Neumann H.P.H. When should genetic testing be obtained in a patient with pheochromocytoma or paraganglioma?. Clin Endocrinol. 2009, 70:354-357.
31. Neumann H.P.H., Erlic Z., Boedecker C.C., Rybicki L.A., Robledo M., Hermsen M., et al. Clinical predictors for germline mutations in head and neck paraganglioma patients: cost reduction strategy in genetic diagnostic process as fall-out. Cancer Res. 2009, 69:3650-3656.